Cargando…
Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
BACKGROUND: Crohn’s disease (CD) is associated with major health services utilization and costs. Between 2012 and 2015, ustekinumab was used off-label in Quebec, Canada for treatment of refractory CD. AIMS: We assessed the direct medical cost of adult CD patients in the 1-year pre- and 1-year postus...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678737/ https://www.ncbi.nlm.nih.gov/pubmed/33241178 http://dx.doi.org/10.1093/jcag/gwz025 |